Dapirolizumab Pegol Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Dapirolizumab Pegol Usage And Synthesis

Uses

Dapirolizumab is a monoclonal antibodi against CD40 ligand. Dapirolizumab targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab attenuates systemic lupus erythematosus[1].

References

[1] Furie RA, et al., Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford). 2021 Nov 3;60(11):5397-5407. DOI:10.1093/rheumatology/keab381

Dapirolizumab Pegol(1416147-64-2)Related Product Information

• Serplulimab
• Dovanvetmab
• Epcoritamab
• Enlimomab
• Cadonilimab
• Immunoglobulin G1,anti-(human NCA-90 granulocyte cell antigen) (mouse monoclonal IMMU-MN3 g1-chain), disulfide with mousemonoclonal IMMU-MN3 k-chain, dimer (9CI)
• Imciromab
• Vadastuximab
• Ragifilimab
• Samalizumab